These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 36305799)

  • 1. Adalimumab Therapy in Pediatric Crohn Disease: A 2-Year Follow-Up Comparing "Top-Down" and "Step-Up" Strategies.
    Payen E; Neuraz A; Zenzeri L; Talbotec C; Abi Nader E; Chatenoud L; Chhun S; Goulet O; Ruemmele FM; Pigneur B
    J Pediatr Gastroenterol Nutr; 2023 Feb; 76(2):166-173. PubMed ID: 36305799
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of infliximab after loss of response of/intolerance to adalimumab in pediatric Crohn's disease: A retrospective multicenter cohort study of the "GETAID pédiatrique".
    Lecoutour A; Dupont C; Caldari D; Dumant C; Vanrenterghem A; Ruiz M; Duclaux-Loras R; Berthet S; Dimitrov G; Lacroix D; Duvant P; Roman C; Wagner AC; Bourmaud A; Viala J; Ruemmele FM; Pigneur B;
    J Pediatr Gastroenterol Nutr; 2024 May; 78(5):1116-1125. PubMed ID: 38314896
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study.
    Kennedy NA; Heap GA; Green HD; Hamilton B; Bewshea C; Walker GJ; Thomas A; Nice R; Perry MH; Bouri S; Chanchlani N; Heerasing NM; Hendy P; Lin S; Gaya DR; Cummings JRF; Selinger CP; Lees CW; Hart AL; Parkes M; Sebastian S; Mansfield JC; Irving PM; Lindsay J; Russell RK; McDonald TJ; McGovern D; Goodhand JR; Ahmad T;
    Lancet Gastroenterol Hepatol; 2019 May; 4(5):341-353. PubMed ID: 30824404
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term outcomes of patients with Crohn's disease who received infliximab or adalimumab as the first-line biologics.
    Inokuchi T; Takahashi S; Hiraoka S; Toyokawa T; Takagi S; Takemoto K; Miyaike J; Fujimoto T; Higashi R; Morito Y; Nawa T; Suzuki S; Nishimura M; Inoue M; Kato J; Okada H
    J Gastroenterol Hepatol; 2019 Aug; 34(8):1329-1336. PubMed ID: 30724387
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adalimumab vs Infliximab in Luminal Pediatric Crohn's Disease: Comparable Outcomes in a Prospective Multicenter Cohort Study.
    deBruyn JC; Huynh HQ; Griffiths AM; Jacobson K; Mack D; Deslandres C; El-Matary W; Otley AR; Church PC; Lawrence S; Wine E; Sherlock M; Critch J; Benchimol EI; Jantchou P; Rashid M; Carroll MW; Bax K; Ricciuto A; Carman N; Walters TD;
    Am J Gastroenterol; 2024 Mar; 119(3):565-575. PubMed ID: 37787642
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of infliximab with adalimumab in biologic-naïve patients with Crohn's disease: a single-center 13-year experience.
    Erdoğan Ç; Durak MB; Alkan A; Kılıç V; Kıvrakoğlu F; Koşar K; Yuksel I
    Eur Rev Med Pharmacol Sci; 2023 Jun; 27(12):5757-5766. PubMed ID: 37401312
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative Effectiveness of Infliximab Versus Adalimumab in Patients with Biologic-Naïve Crohn's Disease.
    Benmassaoud A; Al-Taweel T; Sasson MS; Moza D; Strohl M; Kopylov U; Paradis-Surprenant L; Almaimani M; Bitton A; Afif W; Lakatos PL; Bessissow T
    Dig Dis Sci; 2018 May; 63(5):1302-1310. PubMed ID: 29243105
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [A real-world study focused on the effectiveness and safety of adalimumab as first-line anti-TNF treatment for pediatric Crohn's disease].
    Navas-López VM; Pujol Muncunill G; Llerena E; Navalón Rubio M; Gil-Ortega D; Varea-Calderón V; Sierra Salinas C; Martin-de-Carpi J
    An Pediatr (Engl Ed); 2018 Feb; 88(2):89-99. PubMed ID: 28434894
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-Term Outcomes With Adalimumab Therapy in Pediatric Crohn Disease: Associations With Adalimumab Exposure.
    Rinawi F; Popalis C; Tersigni C; Frost K; Muise A; Church PC; Walters TD; Ricciuto A; Griffiths AM
    J Pediatr Gastroenterol Nutr; 2022 Mar; 74(3):389-395. PubMed ID: 35226647
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Infliximab "Top-Down" Strategy is Superior to "Step-Up" in Maintaining Long-Term Remission in the Treatment of Pediatric Crohn Disease.
    Lee YM; Kang B; Lee Y; Kim MJ; Choe YH
    J Pediatr Gastroenterol Nutr; 2015 Jun; 60(6):737-43. PubMed ID: 25564801
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased effectiveness of early therapy with anti-tumor necrosis factor-α vs an immunomodulator in children with Crohn's disease.
    Walters TD; Kim MO; Denson LA; Griffiths AM; Dubinsky M; Markowitz J; Baldassano R; Crandall W; Rosh J; Pfefferkorn M; Otley A; Heyman MB; LeLeiko N; Baker S; Guthery SL; Evans J; Ziring D; Kellermayer R; Stephens M; Mack D; Oliva-Hemker M; Patel AS; Kirschner B; Moulton D; Cohen S; Kim S; Liu C; Essers J; Kugathasan S; Hyams JS;
    Gastroenterology; 2014 Feb; 146(2):383-91. PubMed ID: 24162032
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of Early Postinduction Adalimumab Exposure With Subsequent Clinical and Biomarker Remission in Children with Crohn's Disease.
    Rinawi F; Ricciuto A; Church PC; Frost K; Crowley E; Walters TD; Griffiths AM
    Inflamm Bowel Dis; 2021 Jun; 27(7):1079-1087. PubMed ID: 32978946
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Propensity Score-matched Comparison of Infliximab and Adalimumab in Tumour Necrosis Factor-α Inhibitor-naïve and Non-naïve Patients With Crohn's Disease: Real-Life Data From the Sicilian Network for Inflammatory Bowel Disease.
    Macaluso FS; Fries W; Privitera AC; Cappello M; Siringo S; Inserra G; Magnano A; Di Mitri R; Mocciaro F; Belluardo N; Scarpulla G; Magrì G; Trovatello A; Carroccio A; Genova S; Bertolami C; Vassallo R; Romano C; Citrano M; Accomando S; Ventimiglia M; Renna S; Orlando R; Rizzuto G; Porcari S; Ferracane C; Cottone M; Orlando A;
    J Crohns Colitis; 2019 Feb; 13(2):209-217. PubMed ID: 30295785
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adalimumab or infliximab as monotherapy, or in combination with an immunomodulator, in the treatment of Crohn's disease.
    Cosnes J; Sokol H; Bourrier A; Nion-Larmurier I; Wisniewski A; Landman C; Marteau P; Beaugerie L; Perez K; Seksik P
    Aliment Pharmacol Ther; 2016 Nov; 44(10):1102-1113. PubMed ID: 27666569
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn's disease (PROFILE): a multicentre, open-label randomised controlled trial.
    Noor NM; Lee JC; Bond S; Dowling F; Brezina B; Patel KV; Ahmad T; Banim PJ; Berrill JW; Cooney R; De La Revilla Negro J; de Silva S; Din S; Durai D; Gordon JN; Irving PM; Johnson M; Kent AJ; Kok KB; Moran GW; Mowat C; Patel P; Probert CS; Raine T; Saich R; Seward A; Sharpstone D; Smith MA; Subramanian S; Upponi SS; Wiles A; Williams HRT; van den Brink GR; Vermeire S; Jairath V; D'Haens GR; McKinney EF; Lyons PA; Lindsay JO; Kennedy NA; Smith KGC; Parkes M;
    Lancet Gastroenterol Hepatol; 2024 May; 9(5):415-427. PubMed ID: 38402895
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The efficacy and safety of either infliximab or adalimumab in 362 patients with anti-TNF-α naïve Crohn's disease.
    Narula N; Kainz S; Petritsch W; Haas T; Feichtenschlager T; Novacek G; Eser A; Vogelsang H; Reinisch W; Papay P
    Aliment Pharmacol Ther; 2016 Jul; 44(2):170-80. PubMed ID: 27226407
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative safety and effectiveness of vedolizumab to tumour necrosis factor antagonist therapy for Crohn's disease.
    Bohm M; Xu R; Zhang Y; Varma S; Fischer M; Kochhar G; Boland B; Singh S; Hirten R; Ungaro R; Shmidt E; Lasch K; Jairaith V; Hudesman D; Chang S; Lukin D; Swaminath A; Sands BE; Colombel JF; Kane S; Loftus EV; Shen B; Siegel CA; Sandborn WJ; Dulai PS;
    Aliment Pharmacol Ther; 2020 Aug; 52(4):669-681. PubMed ID: 32656800
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of adalimumab after infliximab failure in pediatric Crohn disease.
    Fumery M; Jacob A; Sarter H; Michaud L; Spyckerelle C; Mouterde O; Savoye G; Colombel JF; Peyrin-Biroulet L; Gower-Rousseau C; Turck D;
    J Pediatr Gastroenterol Nutr; 2015 Jun; 60(6):744-8. PubMed ID: 26000887
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Favorable Outcomes and Anti-TNF Durability After Addition of an Immunomodulator for Anti-Drug Antibodies in Pediatric IBD Patients.
    Colman RJ; Portocarrero-Castillo A; Chona D; Hellmann J; Minar P; Rosen MJ
    Inflamm Bowel Dis; 2021 Mar; 27(4):507-515. PubMed ID: 32426829
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-TNF Monotherapy for Crohn's Disease: a 13-year Multicentre Experience.
    Peyrin-Biroulet L; Salleron J; Filippi J; Reenaers C; Antunes O; Filipe V; Louis E; Hébuterne X; Roblin X
    J Crohns Colitis; 2016 May; 10(5):516-24. PubMed ID: 26802084
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.